DERMORPHIN - 10 MG

Dermorphin

Course Target: Neuropharmacology, Opioidergic Signaling, and Bioactive Amphibian Toxins.

Core Focal Point: Selective \(\mu \)-Opioid Agonism, Post-Translational Epimerization, and Hyper-Analgesia.

1. Molecular Structure, Origin, & The "Enigma"

Dermorphin is a 7-amino acid heptapeptide (Tyr-D-Ala-Phe-Gly-Tyr-Pro-Ser-NH₂) originally isolated in 1981 from the skin of the South American waxy monkey tree frog (Phyllomedusa sauvagei). 

• The D-Amino Acid Phenomenon: Human DNA only codes for left-handed amino acids (L-isomers). However, Dermorphin features D-Alanine at its second position.

• The Biosynthetic Trick: The frog's genes actually code for standard L-Alanine. After the peptide is built, a highly rare enzyme in the frog's skin physically flips the molecule into its mirror-image D-form.

2. 🎯 The Cellular Mechanism: The Ultra-Lock

To explain its extreme potency to your class, use the phrase "The Stereospecific Lock." Dermorphin operates directly on the central nervous system's primary pain-blocking hardware:

                  [Dermorphin Administered (Exogenous/Frog Toxin)]
                                        │
                                        ▼
                  [Bypasses Rapid Peptidase Destruction (D-Ala Shield)]
                                        │
                                        ▼
             [Selectively Binds to μ-Opioid Receptors (MOR) in Brain/Spine]
                                        │
                                        ▼
             [Inhibits Adenylate Cyclase & Blocks Calcium Influx]
                                        │
                                        ▼
         [Shuts Down Thalamic Firing ──► 30x to 2,000x Potency of Morphine]

Step 1: The Enzymatic Shield

When standard peptides enter the body, protective enzymes (peptidases) immediately tear them apart. Because enzymes are strictly designed to cut L-amino acids, they do not recognize Dermorphin's D-Alanine. This allows Dermorphin to survive un-degraded in biological fluids for long windows. 

Step 2: Severe Receptor Affinity

The D-Alanine residue locks the peptide's N-terminal sequence (Tyr-D-Ala-Phe) into a highly specific geometric shape. This shape fits into the \(\mu \)-Opioid Receptors (MOR) on neurons with near-perfect complementary binding affinity—roughly 100 times tighter than morphine. 

Step 3: Pain Signal Erasure

Binding to MOR triggers an intracellular G-protein cascade that inhibits adenylate cyclase, closes voltage-gated calcium channels, and opens potassium channels. This hyperpolarizes the nerve cell, completely blocking the nucleus from firing or transmitting painful electrical messages to the brain. 

3. Efficacy vs. Morphine (Shocking Lecture Statistics)

Your class will find its raw analgesic power staggering compared to traditional painkillers:

• In Vitro (Isolated Tissue): Dermorphin is 30 to 40 times more potent than morphine.

• Central Administration (In the Brain/Spine): When injected directly into the central nervous system in rodent models, Dermorphin behaves between 752 and 2,170 times more potent than morphineat obliterating pain perception.

• Duration: A single localized dose blocks pain pathways for roughly double the duration of a matched dose of morphine.

RISK.

it can cause severe tachycardia, violent vomiting, and dangerous blood pressure drops.

Addiction and Tolerance: While early research suggested it caused less respiratory depression than morphine, repeated central use still triggers severe opioid tolerance, physical dependence, and intense withdrawal symptoms upon cessation.

Product Details

• Compound: DERMORPHIN
• Quantity: 10 mg
• Form: Lyophilized Powder
• Purity: ≥99% (if applicable)
• Storage: Store in a controlled laboratory environment, protected from light and moisture

Research Use Only
All products supplied by Nexgen Peptide Sciences are intended strictly for laboratory research use. They are not drugs, dietary supplements, food, cosmetics, not intended to diagnose, treat, cure, or prevent any disease or veterinary products, and are not for human or animal consumption.

Regulatory Status
Nexgen Peptide Sciences is a chemical supplier. NexGen Peptide Sciences is not a compounding pharmacy or chemical compounding facility as defined under Section 503A of the Federal Food, Drug, and Cosmetic Act, and is not an outsourcing facility as defined under Section 503B of that Act.

Intended Use and Handling
The products we offer are not intended for human use. They are intended for in-vitro and pre-clinical research purposes only. The customer acknowledges that risks exist in the handling, use, and distribution of these products, and certifies that it has the proper equipment, facilities, and personnel to manage those risks, and knowingly accepts them. These chemicals are not intended to be used, and should not be used, in inappropriate applications — including, without limitation, as food additives, drugs, cosmetics, or household chemicals, or in any application outside of in-vitro laboratory research, pre-clinical research, or laboratory chemical synthesis and materials testing.

Customer Responsibility
By purchasing these products, the customer agrees to the above. In the event the customer uses, or causes others to use, these products outside of these restrictions, the customer accepts all risk of doing so, absolves Nexgen Peptide Sciences of any responsibility for such actions, and agrees to indemnify and hold Nexgen Peptide Sciences harmless against any third-party claims arising from them.

This product is in powder form and is not reconstituted. All materials sold on this site are for laboratory research purposes only and are subject to our Terms and Conditions.

By purchasing, the buyer confirms this product will be used strictly for laboratory research purposes.